Israel Active

UK giant AstraZeneca is teaming up with Tel Aviv University and the Meuhedet and Leumit health funds to launch “Beam” - Illuminating Healthcare Through Data Center. Anonymized data will help AstraZeneca understand disease mechanisms and more.

Israel’s Polyrizon (see previously) announced the successful preliminary safety study for a formulation of its PL-14 Allergy Blocker, marking a significant advancement in the product’s development path.

Israel’s Nanox (see previously) has received US-FDA general use approval for the Nanox.ARC X, its new multi-source digital tomosynthesis system. Its sliced 3D views include the musculoskeletal system, and pulmonary, intra-abdominal and paranasal sinus indications.

Israel’s Sanoculis has received the CE Mark for its MINT (Minimally Invasive Nasal Trabeculostomy) product for the treatment of adult patients undergoing glaucoma angle surgery.  (See MINT and MIMS on Sanoculis website)

Israel’s TopGum (see previously) has launched OMG3! -its new prenatal product which delivers all the crucial nutrients for expectant mothers in a natural fruity chewable. The “all-in-one” gummy houses essential omega-3 fatty acids as the principal ingredient.

A drone stationed on the roof of the Bezio Medical Center is the pilot phase of Israel’s medical drones project. Dubbed “Ziv Eye” it will transport equipment, samples and blood donations between the separate campuses of the Ziv Medical Center, close to the border of Syria and Lebanon.

Neuroscientists at Israel’s Technion Institute have discovered that neural networks in the brain transition from a "beginner" to an "expert" structure when learning a new skill (e.g. playing sport). The process depends on the local release of dopamine in the motor cortex.

The previous article (see ) about a new rapid simple blood test for Parkinson’s Disease didn’t mention that the Hebrew University of Jerusalem had jointly developed the test with Israel’s ATED Therapeutics - a finalist in Fast Company’s 2024 World Changing Ideas.

Researchers at Israel’s Clalit Research Institute & Rabin Medical Center (Beilinson) have discovered that the gene TRIM63 is a major genetic driver and risk factor for hypertrophic cardiomyopathy (HCM), the world’s most common hereditary heart disease. Screening could save many lives.

Researchers from the Hebrew University of Jerusalem and the IDF's Medical Corps have discovered a peptide to activate Protein Kinase C-epsilon (PKC-ε) and significantly improve survival rates of patients (including wounded soldiers) who suffer massive blood loss.